myC: first European-wide patient survey in genomic testing in breast cancer
On the 17th of November 2022, CPE launched the results of the first European-wide patient survey in genomic testing in breast cancer. 4 out of 5 breast cancer patients eligible for genomic testing are not told it is available to them. The survey was completed by a total of 1,383 respondents from five countries (France, Germany, Italy, Spain, UK) over a six-week period in September/October 2022. Eighty-three percent (83%) of respondents had breast cancer; 50% of whom were eligible for genomic testing.
The need for Cancer Patients Europe (CPE)
1. Lack of a Pan European Organisation across the European region with a balanced representation of cancer patients from all European countries
2. Growing need to bridge the European and the national dimensions
3. Only a transparent and credible organization can leverage the current prioritization of cancer care and treatment in Europe for the benefit of cancer patients
Vision and Mission
CPE’s Vision
Reduce the burden of cancer on patients and survivors, their carers, the health care systems and the society as a whole
CPE’s Mission
Represent and empower the voices of cancer patients and cancer survivors towards policymakers and other stakeholders, with the ultimate objective of co-creating policies that drive prevention, high-quality cancer care, treatment and survivorship in Europe.
Values
Partnership and collaboration
Transparency
Patient-centricity
Representativeness
Equity
Strategic priorities
European policies and legislations
Europe’s Beating Cancer Plan
Members’ capacity-building
Patients’ empowerment
Organisational collaboration between the European and national levels
Fundraising
Membership Application Form
Fill up the form to apply to become a member of Cancer Patients Europe